Abstract:Purpose: GNG12 influences a variety of tumors; however, its relationship with glioma remains unclear. The aim of this study was to comprehensively investigate the relationship between GNG12 and the clinical characteristics and prognosis of glioma patients and reveal the mechanisms causing the malignant process of GNG12. Materials and Methods: We obtained information on clinical samples from multiple databases. The expression level of GNG12 was validated using a RT-qPCR and IHC. KM curves were used to assess the correlation between the GNG12 expression and OS of glioma patients. An ROC curve was drawn to assess the predictive performance of GNG12. Univariate and multivariate Cox analyses were performed to analyze the factors affecting the prognosis of patients with glioma. GSEA and TIMER databases were used to estimate the relationship between GNG12 expression, possible molecular mechanisms, and immune cell infiltration. CMap analysis was used to screen candidate drugs for glioma. Subsequent in vitro experiments were used to validate the proliferation and migration of glioma cells and to explore the potential mechanisms by which GNG12 causes poor prognosis in gliomas. Results: GNG12 was overexpressed in glioma patients and GNG12 expression level correlated closely with clinical features, including age and histological type, etc. Subsequently, the K-M survival analysis indicated that the expression level of GNG12 was relevant to the prognosis of glioma, and the ROC curve implied that GNG12 can predict glioma stability. Univariate and multivariate analyses showed that GNG12 represents a risk factor for glioma occurrence. GNG12 expression is closely associated with some immune cells. Additionally, several in vitro experiments demonstrated that down-regulation of GNG12 expression can inhibits the proliferation and migration capacity of glioma cells. Ultimately, the results for the GSEA and WB experiments revealed that GNG12 may promote the malignant progression of gliomas by regulating the cell adhesion molecule cell signaling pathway. Conclusion: In this study, we identified GNG12 as a novel oncogene elevated in gliomas. Reducing GNG12 expression inhibits the proliferation and migration of glioma cells. In summary, GNG12 can be used as a novel biomarker for the early diagnosis of human gliomas and as a potential therapeutic target.

Lnc GNG12-AS1 Knockdown Suppresses Glioma Progression Through the AKT/GSK-3β/β-catenin Pathway.

Lnc GNG12-AS1 knockdown suppresses glioma progression through the AKT/GSK-3β/β-catenin pathway

Long Noncoding RNA LINC00052 Suppressed the Proliferation, Migration and Invasion of Glioma Cells by Upregulating KLF6.

GNG12 as A Novel Molecular Marker for the Diagnosis and Treatment of Glioma

Silencing of Lncrna LBX2-AS1 Suppresses Glioma Cell Proliferation and Metastasis Through the Akt/GSK3β Pathway in Vitro.

lncRNA SNHG16 Exerts Oncogenic Functions in Promoting Proliferation of Glioma Through Suppressing p21

Long Noncoding RNA Lncherg Promotes Cell Proliferation, Migration and Invasion in Glioblastoma

Upregulation of the Long Non-Coding RNA SNHG1 Predicts Poor Prognosis, Promotes Cell Proliferation and Invasion, and Reduces Apoptosis in Glioma.

LncRNA LINC01018/miR‐942‐5p/KNG1 Axis Regulates the Malignant Development of Glioma in Vitro and in Vivo

FGD5-AS1 Facilitates Glioblastoma Progression by Activation of Wnt/β-catenin Signaling Via Regulating Mir-129-5p/hnrnpk Axis

Long Intergenic Noncoding RNA 00152 Promotes Glioma Cell Proliferation and Invasion by Interacting with MiR-16

Impact of Nuclear Peripheral Chromatin Lamin LMNB1 Gene in the Proliferation and Migration of Glioma Cells

A Long Noncoding Rna Zeb1-As1 Promotes Tumorigenesis and Predicts Poor Prognosis in Glioma

A novel lncRNA, RPL34-AS1, promotes proliferation and angiogenesis in glioma by regulating VEGFA

Long non-coding RNA DDX11-AS1 promotes the proliferation and migration of glioma cells by combining with HNRNPC

Long non-coding RNA LINC00174 promotes glycolysis and tumor progression by regulating miR-152-3p/SLC2A1 axis in glioma

Lnc-Nlc1-c Inhibits Migration, Invasion and Autophagy of Glioma Cells by Targeting Mir-383 and Regulating PRDX-3 Expression.

LncRNA SNHG6 Acts As a Prognostic Factor to Regulate Cell Proliferation in Glioma Through Targeting P21

In Silico Analysis Identifies Upregulated Lncrna DLGAP1-AS1 Which is Correlated to Poor Prognosis and Promotes Cell Proliferation in Glioblastoma

ZNF503-AS2 is a Promising Therapeutic Target and is Associated with the Immune Microenvironment in Glioma

Function of Long Noncoding RNAs in Glioma Progression and Treatment Based on the Wnt/β-Catenin and PI3K/AKT Signaling Pathways